Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
BioSpace8h
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Medscape23h
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Healio20h
GLP-1 may have potential to improve poststroke outcomes, prognosis
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
Medscape15h
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
WHYY20h
After success with weight loss GLP-1 drugs, IBX patients face high costs after insurer drops coverage for obesity
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.